Skip to content

The different intervention strategies to explore the objective evaluation of ''blood pathways blocked'' and ''qi pathways blocked'' of coronary atherosclerosis

The different intervention strategies to explore the objective evaluation of ''blood pathways blocked'' and ''qi pathways blocked'' of coronary atherosclerosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035940
Enrollment
Unknown
Registered
2020-08-20
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patient meets the diagnostic criteria for coronary atherosclerotic heart disease, has a clear history of myocardial infarction, or coronary angiography or coronary CT confirmed coronary artery stenosis >=50%, and the severity of angina pectoris is I-II/I-III; 2. Those who meet the syndrome differentiation criteria of impassable qi and blood vessels in traditional Chinese medicine for coronary heart disease; 3. Aged 18 to 75 years old; 4. those who voluntarily sign written informed consent.

Exclusion criteria

Exclusion criteria: (1) Acute myocardial infarction combined with severe complications such as cardiogenic shock (cannot be corrected by conventional treatment), combined with mechanical complications; (2) combined with other heart diseases or severe cardiac insufficiency (NYHA cardiac function classification> III); (3) Acute coronary syndrome (ACS) patients with asymptomatic or stable symptoms; (4) Patients with chronic kidney disease with severe heart, lung, liver and other vital organ dysfunction; severe primary diseases, such as hematopoiesis Systemic and/or severe heart, lung, liver and other vital organ dysfunction; (5) recent cerebrovascular accidents, major operations and trauma history; (6) Patients with chronic kidney disease and severe heart, lung, liver and other vital organ dysfunction; (7) Patients with severe uncontrolled hypertension (systolic blood pressure >=180mmHg or diastolic blood pressure >=110mmHg); (8) Severe arrhythmia (ventricular bisection, ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block, cardiac Cardiac arrest, severe sinus tachycardia and bradycardia, sick sinus syndrome, reentrant supraventricular tachycardia, arrhythmia leading to hemodynamic changes); (9) allergic constitution, or more People who are allergic to foods of various drugs, or those who are known to be allergic to the components of the drug; (10) Patients who have participated in other clinical trials or are taking other proprietary Chinese medicines within one month; (11) Patients who are pregnant, preparing to become pregnant, and breastfeeding Women; (12) Patients with mental, psychological and other problems that do not match the completion of the study.

Design outcomes

Primary

MeasureTime frame
Angina pectoris curative effect observation index;

Countries

China

Contacts

Public ContactDeyu Fu

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

fdy65@126.com+86 13801833089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026